DK1483290T3 - Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger - Google Patents

Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger

Info

Publication number
DK1483290T3
DK1483290T3 DK03729533T DK03729533T DK1483290T3 DK 1483290 T3 DK1483290 T3 DK 1483290T3 DK 03729533 T DK03729533 T DK 03729533T DK 03729533 T DK03729533 T DK 03729533T DK 1483290 T3 DK1483290 T3 DK 1483290T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
peptides
potentiate
treatments
acid damaging
Prior art date
Application number
DK03729533T
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1483290T3 publication Critical patent/DK1483290T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03729533T 2002-01-17 2003-01-17 Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger DK1483290T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35020802P 2002-01-17 2002-01-17
PCT/IB2003/000425 WO2003059942A2 (en) 2002-01-17 2003-01-17 Peptides and peptidomimetics having anti-proliferative activity and their use

Publications (1)

Publication Number Publication Date
DK1483290T3 true DK1483290T3 (da) 2008-11-03

Family

ID=23375680

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03729533T DK1483290T3 (da) 2002-01-17 2003-01-17 Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger

Country Status (19)

Country Link
US (3) US6995135B2 (da)
EP (1) EP1483290B1 (da)
JP (3) JP4041066B2 (da)
KR (2) KR100863090B1 (da)
CN (2) CN100360564C (da)
AT (1) ATE404584T1 (da)
AU (2) AU2003235576C1 (da)
CA (1) CA2471192C (da)
CY (1) CY1108470T1 (da)
DE (1) DE60322845D1 (da)
DK (1) DK1483290T3 (da)
ES (1) ES2311703T3 (da)
HK (1) HK1069179A1 (da)
IL (2) IL162836A0 (da)
NO (1) NO332461B1 (da)
PT (1) PT1483290E (da)
SI (1) SI1483290T1 (da)
WO (1) WO2003059942A2 (da)
ZA (1) ZA200405455B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162836A0 (en) * 2002-01-17 2005-11-20 Canbas Co Ltd Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
US7030111B2 (en) * 2002-06-06 2006-04-18 Canbas Co., Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
US20090238811A1 (en) * 2002-09-09 2009-09-24 Mcdaniel C Steven Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
US20110070376A1 (en) * 2002-09-09 2011-03-24 Reactive Surfaces, Ltd. Anti-fouling Paints & Coatings
US20100233146A1 (en) * 2002-09-09 2010-09-16 Reactive Surfaces, Ltd. Coatings and Surface Treatments Having Active Enzymes and Peptides
US20100210745A1 (en) * 2002-09-09 2010-08-19 Reactive Surfaces, Ltd. Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
JP4705567B2 (ja) * 2003-06-25 2011-06-22 株式会社 キャンバス 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
US8618066B1 (en) 2003-07-03 2013-12-31 Reactive Surfaces, Ltd., Llp Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations
EP1664340A1 (en) * 2003-08-08 2006-06-07 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
US20060286006A1 (en) * 2005-06-21 2006-12-21 Mcdaniel C S Method and apparatus for the treatment of fluid waste streams
US20100135903A1 (en) * 2006-10-11 2010-06-03 Medvet Science Pty. Ltd. Use of a dna damaging agent and a ligand for the treatment of cancer
US9178387B2 (en) * 2008-05-13 2015-11-03 Qualcomm Incorporated Receive antenna for wireless power transfer
PE20091924A1 (es) * 2008-05-14 2010-01-04 Takeda Pharmaceutical Compuesto peptidico y su uso
US8388904B1 (en) 2008-12-22 2013-03-05 Reactive Surfaces, Ltd., Llp Equipment decontamination system and method
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
EP3041491A1 (en) * 2011-08-31 2016-07-13 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
PT3013351T (pt) * 2013-06-24 2020-01-17 Canbas Co Ltd Péptidos e peptidomiméticos em utilizações e tratamentos combinados para subpopulações de pacientes com cancro
HUE045872T2 (hu) 2014-05-21 2020-01-28 Entrada Therapeutics Inc Sejteket penetráló peptidek és ezek elõállítására és alkalmazására szolgáló eljárások
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
EP3185880B1 (en) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
TW201945014A (zh) 2018-02-22 2019-12-01 美商安卓達治療股份有限公司 用於治療粒線體性神經胃腸腦病變之組合物及方法
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN114989254B (zh) * 2022-06-17 2023-11-03 中山大学 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1218494T3 (da) * 1999-09-22 2005-08-08 Canbas Co Ltd Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
IL162836A0 (en) * 2002-01-17 2005-11-20 Canbas Co Ltd Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

Also Published As

Publication number Publication date
IL162836A (en) 2011-09-27
WO2003059942A9 (en) 2003-11-27
AU2009201711B2 (en) 2011-12-15
US20040248783A1 (en) 2004-12-09
KR101103412B1 (ko) 2012-01-06
WO2003059942A2 (en) 2003-07-24
ATE404584T1 (de) 2008-08-15
NO20043381L (no) 2004-10-12
AU2009201711A1 (en) 2009-05-21
AU2003235576B2 (en) 2009-01-29
AU2003235576A1 (en) 2003-07-30
US20060084610A1 (en) 2006-04-20
PT1483290E (pt) 2008-09-19
CN1642978A (zh) 2005-07-20
CY1108470T1 (el) 2014-04-09
US7476657B2 (en) 2009-01-13
JP4873646B2 (ja) 2012-02-08
NO332461B1 (no) 2012-09-24
US6995135B2 (en) 2006-02-07
JP2008044946A (ja) 2008-02-28
ZA200405455B (en) 2005-08-31
CA2471192A1 (en) 2003-07-24
HK1069179A1 (en) 2005-05-13
EP1483290B1 (en) 2008-08-13
AU2003235576C1 (en) 2009-12-10
ES2311703T3 (es) 2009-02-16
CA2471192C (en) 2014-05-20
CN100360564C (zh) 2008-01-09
CN101092455B (zh) 2012-07-04
CN101092455A (zh) 2007-12-26
DE60322845D1 (de) 2008-09-25
EP1483290A2 (en) 2004-12-08
KR100863090B1 (ko) 2008-10-13
WO2003059942A3 (en) 2004-10-07
JP2005529845A (ja) 2005-10-06
KR20080006649A (ko) 2008-01-16
US20090253635A1 (en) 2009-10-08
SI1483290T1 (sl) 2009-02-28
KR20040081750A (ko) 2004-09-22
JP4041066B2 (ja) 2008-01-30
JP2011037896A (ja) 2011-02-24
IL162836A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
DK1483290T3 (da) Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger
CY1122523T1 (el) Πεπτιδια και πεπτιδομιμητικα σε συνδυαστικες χρησεις και αγωγες για υποπληθυσμους πασχοντων απο καρκινο
NO20055211L (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
WO2005100392A3 (en) Treatment of neuropathic pain with zinc finger proteins
EA201000078A1 (ru) Инъекционная дерматологическая композиция для лечения морщин
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
BRPI0414497A (pt) análogos de talidomida
DE60326453D1 (de) Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
BRPI0502841A (pt) uso de produtos de legume para o tratamento e prevenção de dano à pele induzido por radioterapia
DK1539724T3 (da) Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
MXPA05004133A (es) Nuevos compuestos antitumorales.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EP1827471A4 (en) COMPOSITION AND METHOD FOR INCREASING APOPTOSIS OF CANCER CELLS
NO20070485L (no) Anvendelse av bakteriofag- og profagproteiner i genterapi ved kreftbehandling.
ATE425247T1 (de) Synthetische peptide und ihre vorbeugende oder therapeutische anwendung für krebsinvasion und metastasen
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
SE0202464D0 (sv) Use of compounds
HK1082261A1 (en) 4-methylhexanoic kahalalide f compound
ATE390144T1 (de) Behandlung von fibrosen
WO2024086708A3 (en) Compositions and methods for preventing cardiomyopathy